Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 4/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21243961 | 0.88 | SRC (0.35) | SRCEGFRALDH1A1NPSR1CHEK1 | |
| SCHEMBL15434235 | 0.81 | SRC (0.39) | SRCEGFRALDH1A1NPSR1CHEK1 | |
| SCHEMBL855822 | 0.76 | PARP1 (0.41) | SRCEGFRALDH1A1NPSR1CHEK1 | |
| SCHEMBL30850388 | 0.73 | PARP1 (0.48) | ALDH1A1TSHRKDM4E | |
| SCHEMBL2085627 | 0.72 | HTT (0.58) | ALDH1A1NPSR1CHEK1TSHRHTT | |
| SCHEMBL1073971 | 0.70 | — | — | |
| SCHEMBL30850266 | 0.70 | TNKS2 (0.36) | ALDH1A1TSHR | |
| SCHEMBL14603966 | 0.69 | TNKS2 (0.44) | SRCALDH1A1NPSR1CHEK1TSHR | |
| SCHEMBL23923109 | 0.68 | P2RX3 (0.36) | — | |
| SCHEMBL2624085 | 0.68 | TSHR (0.49) | SRCALDH1A1NPSR1CHEK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12071434-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-08-27 | — | — | US | disclosed |
| CN-118480029-A | 2-Aminopyrimidine compound or salt thereof, and preparation method and application thereof | 励缔(杭州)医药科技有限公司 | 2024-08-13 | — | — | CN | disclosed |
| EP-3895707-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-10-04 | — | — | EP | disclosed |
| US-20230042358-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-09 | — | — | US | disclosed |
| EP-3895707-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230042358-A1 | HETEROCYCLIC COMPOUND | HCRTR2, HCRTR1, NTSR2 | SRC 4130/4885EGFR 4759/4885ALDH1A1 1746/4885 |
| US-12071434-B2 | Heterocyclic compound | HCRTR2, HCRTR1, NTSR2 | SRC 4130/4885EGFR 4759/4885ALDH1A1 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.